Teva upped to Outperform by Oppenheimer

From Perform; target $12

https://www.benzinga.com/stock/TEVA/ratings

NextCure started at Overweight by Morgan Stanley

Target $25

https://www.benzinga.com/stock/NXTC/ratings

NextCure started at Overweight by Piper Jaffray

Target $26.

https://www.benzinga.com/stock/NXTC/ratings

Molina upped to Outperform by BMO

From Market Perform; target to $200 from $154.

https://www.benzinga.com/stock/MOH/ratings

Five Prime cut to Market Perform by Wells Fargo

From Outperform; target to $10 from $35.

https://www.benzinga.com/stock/FPRX/ratings

Cortexyme started at Buy at Canaccord

Target $42.

https://www.benzinga.com/stock/CRTX/ratings

Axcella started at Overweight by JPMorgan

Target $20.

https://www.benzinga.com/stock/AXLA/ratings